← Back to Search

Other

AVTX-002 for Asthma

Phase 2
Waitlist Available
Research Sponsored by Cerecor Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are you 5 foot 10 inches tall, or taller?
Do you continue to experience asthma symptoms despite taking your medication as prescribed?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through week 14
Awards & highlights

Study Summary

This trial is testing a new medication to see if it helps people with asthma that isn't helped by other medications.

Eligible Conditions
  • Non-Eosinophilic Asthma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are at least 70 inches tall.
Select...
Even after taking your asthma medicine as directed by your doctor, you still have symptoms of asthma.
Select...
Have you ever smoked cigarettes in the past or are you currently smoking?
Select...
Do you have any lung disease other than asthma?
Select...
In the last six months, have you taken medication that weakens your immune system?

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through week 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and through week 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the ability of AVTX-002 to improve asthma control in subjects with poorly controlled non-eosinophilic asthma (NEA) based on the proportion of patients who experience asthma related events.
Secondary outcome measures
To assess the safety and tolerability of AVTX-002.
To evaluate biomarkers of pharmacodynamic (PD) activity and mechanism of action of AVTX-002.
To evaluate the immunogenicity of AVTX-002.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AVTX-002Experimental Treatment1 Intervention
Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
Group II: PlaceboPlacebo Group1 Intervention
Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AVTX-002
2022
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Cerecor IncLead Sponsor
8 Previous Clinical Trials
1,821 Total Patients Enrolled
Avalo Therapeutics, Inc.Lead Sponsor
11 Previous Clinical Trials
1,835 Total Patients Enrolled
Garry Neil, MDStudy DirectorAvalo Therapeutics, Inc.
2 Previous Clinical Trials
6 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the number of participants that are enrolled in this clinical investigation?

"Affirmative. The information housed on clinicaltrials.gov verify that this research, which was first published on February 24th 2022, is actively recruiting participants. Eighty individuals must be recruited from a total of 24 different medical sites."

Answered by AI

Is participation in this experiment available to patients at the present time?

"According to the information provided on clinicaltrials.gov, this investigation is ongoing and still trying to locate suitable patients. It was first launched on February 24th 2022 and has since been adjusted as of November 15th 2022."

Answered by AI

How does AVTX-002 impact patient safety?

"Given that the trial is currently in Phase 2, which implies a degree of safety has been established but without any efficacy data, we have assigned AVTX-002 a score of 2."

Answered by AI

Is this research initiative currently being conducted in various locations across the United States?

"ASHA Clinical Research-Munster, LLC in Hammond, Indiana, Helix Biomedics, LLC in Boynton Beach, Florida and Family Allergy and Asthma Research Institute in Louisville Kentucky are amongst the 24 sites selected to host this clinical trial."

Answered by AI

Who else is applying?

What state do they live in?
Maryland
Florida
Texas
Other
How old are they?
65+
18 - 65
What site did they apply to?
Allergy and Asthma Medical Group of the Bay Area
National Jewish Health
Meridian Clinical Research
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0

What questions have other patients asked about this trial?

How long would the trial be? Would you have to be in state for it?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

I’ve had asthma since I was 7, it has progressively gotten better and worse at different times, but never fully gotten better in a consistent pattern.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Meridian Clinical Research: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
2022. "A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05288504.
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top